Stoke Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Stoke Therapeutics, Inc. (STOK) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $10.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-03
- Stoke Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $10.80M, a 42.17% increase year-over-year.
- Stoke Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.75M, a 29.62% increase year-over-year.
- Stoke Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.04M, a 7.27% increase year-over-year.
- Stoke Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.60M, a 2.30% increase year-over-year.
- Stoke Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $32.24M, a 17.36% increase from fiscal 2024.
- Stoke Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $27.47M, a 8.76% increase from fiscal 2023.
- Stoke Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $25.26M, a 10.51% increase from fiscal 2022.
- Stoke Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $22.85M, a 38.93% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.80M 10-Q · filed 2026-08-03 | $19.55M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $8.75M 10-Q · filed 2026-08-03 | |||
| 2025-12-31 | $32.24M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $8.04M 10-Q · filed 2025-11-04 | $15.64M derived: sum of 2 quarters · filed 2026-08-03 | $22.39M derived: sum of 3 quarters · filed 2026-08-03 | |
| 2025-06-30 | $7.60M 10-Q · filed 2026-08-03 | $14.35M derived: sum of 2 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $6.75M 10-Q · filed 2026-08-03 | |||
| 2024-12-31 | $27.47M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $7.49M 10-Q · filed 2025-11-04 | $14.92M derived: sum of 2 quarters · filed 2025-11-04 | $20.33M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $7.43M 10-Q · filed 2025-11-04 | $12.84M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $5.41M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $25.26M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $6.55M 10-Q · filed 2024-11-05 | $13.31M derived: sum of 2 quarters · filed 2024-11-05 | $19.20M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $6.76M 10-Q · filed 2024-11-05 | $12.65M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $5.89M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $22.85M 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $5.93M 10-Q · filed 2023-11-07 | $12.09M derived: sum of 2 quarters · filed 2023-11-07 | $17.06M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $6.16M 10-Q · filed 2023-11-07 | $11.14M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $4.97M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $16.45M 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $4.61M 10-Q · filed 2022-11-14 | $9.07M derived: sum of 2 quarters · filed 2022-11-14 | $11.76M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $4.45M 10-Q · filed 2022-11-14 | $7.15M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $2.70M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $5.77M 10-K · filed 2022-03-10 | |||
| 2020-09-30 | $1.78M 10-Q · filed 2021-11-08 | $3.43M derived: sum of 2 quarters · filed 2021-11-08 | $4.19M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $1.65M 10-Q · filed 2021-11-08 | $2.40M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $754.00K 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $1.92M 10-K · filed 2021-03-09 | |||
| 2019-09-30 | $731.00K 10-Q · filed 2020-11-12 | $1.03M derived: sum of 2 quarters · filed 2020-11-12 | $1.21M derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $298.00K 10-Q · filed 2020-11-12 | $479.00K derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | $181.00K 10-Q · filed 2020-11-12 | |||
| 2018-12-31 | $240.00K 10-K · filed 2020-03-23 | |||
| 2018-09-30 | $40.00K 10-Q · filed 2019-11-12 | $117.00K derived: sum of 2 quarters · filed 2019-11-12 | $121.00K derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $77.00K 10-Q · filed 2019-11-12 | $81.00K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $4.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |